Two New Molecules Show Early Promise in Treating Alzheimer’s

Two New Molecules Show Early Promise in Treating Alzheimer’s
Molecules blocking a receptor found in the brain called 5-HT6R could potentially be used to treat Alzheimer’s disease, according to two studies led by researchers at Moscow Institute of Physics and Technology (MIPT), according to a news release. The first study “AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer’s Disease,” published in the scientific journal Molecular Pharmaceutics, describes the effects of a molecule called AVN-211 in cells grown in the laboratory as well as in animal models of the disease. The researchers first demonstrated that AVN-211 is indeed capable of blocking the 5-HT6R receptor in cells. They found that the compound was able to block the receptor more selectively and effectively than other compounds, even those that are currently in clinical trials. They then analyzed how the compound is metabolized and with which other molecules it interacts. The researchers then moved onto animal experiments where they observed the pharmacokinetics, or concentration changes of the compound in the blood of the animals. They also tested the toxicity of the compound and found that it was low. Finally, they conducted memory disorder stress tests and showed that AVN-211 may be able to improve memory function in mice and rats. First, they trained the animals to find an exit from a maze while they were under the influence of drugs causing memory loss. When
Subscribe or to access all post and page content.